Nogo receptor homologs
CA 2424834 A1 · Owner: Biogen, Inc. · Inventors: Sah, Dinah W. Y.; Cate, Richard L.; Strittmatter, Stephen M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encodign NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides proteins and , antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial o cerebral trauma, sprial cord injury stroke or a demyelinating , disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 6, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.